Atle Brynestad is Executive Vice President for the South-Eastern Norway Regional Health Authority and has been Chairman of the board for RADFORSK since 2007.
Brynestad has vast experience from both private and public sector. Since the beginning of the millennium he has been working with business development and management within the field of healthcare, and also had management positions at Sykehuspartner and Ministry of Health and Care Services.
Over the past 25 years, Brynestad has been a member of the board for a variety of organizations, such as The Norwegian Export Credit Guarantee Agency, Norlax AS and T-Invest AS.
Inger Sandlie is Professor of Molecular Biology and Deputy Director of the Center for Immune Regulation, University of Oslo. She holds a PhD from the University of Bergen and did postdocs at Johns Hopkins University, USA and the Norwegian Radium Hospital.
Sandlie heads an active research group and is co-inventor of more than 10 patents that describe the production and use of modified antibodies and albumin.
Furthermore, she is cofounder of two biotechnology companies, Vaccibody A/S and Nextera A/S, and has had extensive research collaboration with Novozymes A/S. In 2011, she received the first Innovation Prize awarded by the University of Oslo.
Ingar Pettersen is Chairman of the Board for Universitetssykehus Fondsstiftelse, Norsk medisinsk Syklotronsenter AS, Enter Kompetanse AS and Bråset bo- og omsorgssenter IKS, as well as a board member for Lovisenberg Diakonale Sykehus AS.
Pettersen has vast experience from both private and public sector, working specifically with restructuring of organizations. He is a former CEO for Stavanger Universitetssykehus HF and Ullevål sykehus.
He has also been acting director of the National Museum of Art, Architecture and Design and CEO for Dagsavisen AS og Østfoldpressen AS.
Bente-Lill Romøren is a consultant in Business Development and Management and board member in Targovax
She is former CEO of Novo Nordisk Scandinavia with 40 years of experience gained from national and international management positions in the pharmaceutical industry. Her experience spans senior management, marketing, sales, business development, licensing, market access, public affairs, clinical trials and lifecycle management.
She also has good knowledge of the health care system and of regulations and framework for the pharmaceutical market.
Erlend B. Smeland is Director for Research, Innovation and Education at Oslo University Hospital and Professor at University of Oslo.
He has been Head of Institute for Cancer Research and has been Research Director in South-Eastern Norway Regional Health Authority and Chairman of the Board in the Norwegian Cancer Society. He is also member of the board of Inven2 and has been a board member in the FORNY program in the Research Council of Norway.
He leads a research group at Institute for Cancer Research, which is one of 6 groups in Centre for Cancer Biomedicine (CoE). He received King Olav Vs Cancer Research Prize in 2004.